Long-term survival in a patient with BRCA2-mutated pleomorphic anaplastic pancreatic carcinoma treated with Olaparib maintenance therapy
Authors:
- 15 February 2026
- journal article
- case report
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 19 (2) , 435-440
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- The genomic landscape of 2,023 colorectal cancersNature, 2024
- Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activityEBioMedicine, 2020
- Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas harboring KRAS and BRCA mutations: case report and whole exome sequencing analysisBMC Gastroenterology, 2020
- Emerging strategies in BRCA-positive pancreatic cancerJournal of Cancer Research and Clinical Oncology, 2018
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trialThe Lancet, 2016
- Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriersBritish Journal of Cancer, 2014
- Clinical Outcomes for Anaplastic Pancreatic Cancer: A Population-Based StudyJournal of the American College of Surgeons, 2012
- Anaplastic pancreatic cancer: Presentation, surgical management, and outcomeSurgery, 2011
- Endoscopic Ultrasound-Guided Fine-Needle Aspiration for the Diagnosis of Anaplastic Pancreatic CarcinomaPancreas, 2010
- A clinicopathologic and immunohistochemical study of 35 anaplastic carcinomas of the pancreas with a review of the literatureAnnals of Diagnostic Pathology, 2001